Prognostic Implications of AccuFFRangio-guided PCI in STEMI
Sponsored by Wuhan Asia Heart Hospital
About this trial
Last updated 4 years ago
Study ID
AFCA20220105
Status
Unknown
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Ended 3 years ago
What is this trial about?
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The aim of this study was to evaluate the diagnostic accuracy and prognostic implications of AccuFFRangio in patients with ST-segment elevation myocardial infarction (STEMI).
What are the participation requirements?
Inclusion Criteria
* 18 Years and older
* STEMI patients with primary percutaneous coronary intervention within 24 hours with at least 1 non-IRA
* Diameter stenosis of 50%-90% by visual estimate
* Reference vessel size > 2 mm in stenotic segment by visual estimate
Exclusion Criteria
* LVEF ≤ 40%
* eGFR < 60 mL/min
* Allergy to contrast media, adenosine
* Prior CABG